Browse the evidence

LSD1's ability to repress energy-expenditure genes is strictly dependent on cellular FAD (flavin adenine dinucleotide) levels, linking nutritional status to epigenetic control.

The enzyme LSD1, which suppresses fat-burning genes, requires FAD to work. If cellular FAD levels are low, LSD1 cannot repress these genes, leading to increased energy expenditure. This suggests that maintaining adequate levels of riboflavin (Vitamin B2), a precursor to FAD, may support healthy epigenetic regulation of metabolism.

High-fat diet (HFD) feeding in mice leads to elevated LSD1 expression and reduced expression of energy-expenditure genes in white adipose tissue, which can be reversed by inhibiting LSD1.

In mice, a high-fat diet increases the levels of LSD1 in fat tissue, which in turn suppresses genes responsible for burning fat. This creates a biological state where the body is less efficient at energy expenditure. Inhibiting LSD1 can reverse this effect, suggesting that targeting this pathway might help counteract the metabolic adaptations caused by high-fat diets.

Higher early adult BMI (ages 18-30) is inversely associated with breast cancer risk in both pre- and postmenopausal women, suggesting a protective effect of higher adiposity during young adulthood.

Maintain a healthy weight during young adulthood (18-30), as higher early adult BMI may offer some protection against breast cancer later in life. However, avoid adult weight gain, which increases risk.

In normotensive premenopausal women, visceral adipose tissue (VAT) and insulin resistance are directly associated with elevated plasma aldosterone levels, independent of plasma renin activity.

For women, reducing visceral fat through weight loss is likely to lower aldosterone levels, which may help manage blood pressure and cardiovascular risk, independent of standard kidney-based hormone regulation. This suggests that visceral fat reduction has specific hormonal benefits for women that may not be as pronounced in men.

Rapid nutrition transition toward energy-dense, micronutrient-poor diets in sub-Saharan Africa drives a double burden of disease, characterized by the simultaneous emergence of obesity/NCDs and persistent under-nutrition.

In rapidly urbanizing African contexts, simply increasing food availability is not enough. Public health strategies must simultaneously address calorie excess (obesity/NCDs) and nutrient deficiency (stunting/micronutrients) by promoting holistic, integrated dietary guidelines that prioritize whole foods and limit processed, energy-dense items.

Fetal programming and early-life under-nutrition (stunting) increase vulnerability to obesity and metabolic syndrome when individuals are exposed to modern, energy-dense diets during the nutrition transition.

For individuals with a history of childhood stunting or under-nutrition, standard weight loss advice may be less effective due to metabolic programming. Interventions should focus on high-quality nutrient density rather than just caloric restriction, and early-life nutrition is critical to prevent this vulnerability.

Regulatory T (Treg) cells exert an attenuating effect on insulin resistance and hepatic inflammation in NAFLD and obesity, primarily through the secretion of inhibitory cytokines IL-10 and TGF-beta and PPAR-gamma-dependent functionality.

In obesity and NAFLD, the body's natural regulatory T cells (Tregs) are often depleted or dysfunctional, contributing to insulin resistance and liver damage. Restoring Treg function (e.g., via PPAR-gamma agonists like pioglitazone in clinical settings) can improve glucose tolerance and reduce liver inflammation. Lifestyle interventions that reduce adipose tissue inflammation may help preserve Treg numbers.

Th17 cells promote liver inflammation, fibrosis, and insulin resistance in NAFLD and obesity, primarily through IL-17 secretion which stimulates pro-inflammatory cytokine release and hepatic stellate cell activation.

High levels of Th17 cells and IL-17 are associated with worse insulin resistance and liver fibrosis in obesity and NAFLD. Reducing systemic inflammation through weight loss and metabolic control may lower Th17 activity, thereby improving insulin sensitivity and slowing liver disease progression.

Long-acting Fc-fusion GDF15 molecules reduce body weight and improve metabolic profiles in obese models by delaying gastric emptying, altering food preference, and activating area postrema neurons.

This research suggests that engineered GDF15 therapies could effectively treat obesity by slowing digestion and changing food preferences via brain signaling. While currently in preclinical stages, the weekly dosing schedule of these long-acting variants offers a promising alternative to daily oral medications for metabolic disorders.

In euthyroid obese individuals, elevated serum TSH is an adaptive physiological response to increased thyroid hormone disposal driven by larger body size, rather than primary hypothyroidism.

If you are obese but your thyroid hormones (T3/T4) are normal, a slightly high TSH is likely just your body's natural way of managing a larger size. It usually goes away when you lose weight. Current evidence does not support using thyroid medication to treat this isolated high TSH in obese people.

Leptin acts as a critical signal from adipose tissue to the hypothalamus to regulate the hypothalamus-pituitary-thyroid axis, specifically by stimulating TRH expression and TSH secretion during energy sufficiency.

Your body uses leptin (a hormone from fat cells) to tell your brain how much energy you have. When you fast or lose weight, leptin drops, signaling your brain to slow down thyroid function to save energy. This is a normal survival mechanism.

Deletion of intestinal epithelial MyD88 in mice prevents diet-induced obesity and metabolic disorders by increasing energy expenditure and improving gut barrier function, an effect mediated by changes in gut microbiota composition.

This research suggests that the health of your intestinal lining and its interaction with gut bacteria play a critical role in whether your body stores fat or burns energy, especially when eating a high-fat diet. While this study used genetic modification in mice, it implies that maintaining gut barrier integrity and a healthy microbiome might be key strategies for preventing obesity-related metabolic issues.

Targeting intestinal epithelial MyD88 therapeutically reduces fat mass and inflammation even after obesity is established, suggesting a potential treatment for existing obesity.

This study suggests that even after obesity develops, interventions that support intestinal health and reduce inflammation might help reverse fat gain. For now, this translates to focusing on dietary patterns that support gut barrier integrity and a diverse microbiome, rather than waiting for specific pharmaceutical targets.

Plasma IL-15 protein levels increase acutely after resistance exercise but do not change chronically with training and are not associated with variability in muscle responses.

Measuring blood IL-15 levels is not a useful predictor of who will gain muscle from resistance training. Focus on consistent training and nutrition rather than trying to manipulate circulating IL-15 levels.

Loss of the circadian clock gene Bmal1 in skeletal muscle causes systemic glucose intolerance and hyperglycemia by impairing insulin-stimulated glucose uptake and reducing GLUT4 expression.

Maintaining a consistent sleep-wake cycle is critical for metabolic health. Your skeletal muscles rely on their internal circadian clock to efficiently process glucose. Disrupting this rhythm (e.g., through irregular sleep or shift work) can impair insulin sensitivity and glucose tolerance, contributing to higher blood sugar levels and increased diabetes risk.

Higher levels of perceived loneliness are associated with increased objective sleep fragmentation, independent of sleep duration, negative affect, and demographic factors.

If you feel lonely, your sleep may be breaking up into more fragments, even if you are in bed for the usual amount of time. This is a biological stress response to feeling unsafe socially, not just a mood issue. Focus on creating a sense of security and connection, as this may help restore sleep continuity more effectively than just trying to extend total sleep time.

Loss of proteostasis, characterized by the accumulation of abnormal proteins due to decreased cellular capacity to degrade them, is a hallmark of aging and contributes to age-related pathologies like neurodegenerative diseases.

As we age, our cells become less efficient at cleaning up damaged proteins, leading to accumulation that can cause diseases like Alzheimer's. Maintaining cellular 'housekeeping' through healthy lifestyle choices (like exercise and diet) may help support these natural degradation pathways.

Insulin resistance (IR) fundamentally alters the association between specific lipid subclasses and clinical health markers, causing lipid profiles to diverge significantly from those seen in insulin-sensitive (IS) individuals.

If you have insulin resistance, standard lipid markers (like LDL/HDL ratios) may not predict your health risks the same way they do for healthy people. Your lipid profile's relationship with inflammation and blood sugar changes. Relying solely on standard lipid panels without assessing insulin sensitivity (e.g., fasting insulin, HOMA-IR, or SSPG) may miss critical metabolic risks.

During acute respiratory viral infections (RVIs), specific lipid subclasses (small TAGs, LPCs, ether-linked PEs) undergo dynamic, phase-dependent changes that correlate with immune response and energy metabolism shifts.

Your lipid profile is not static during illness. Small TAGs drop sharply early in infection (possibly for energy), while LPCs and ether-linked PEs drop later, correlating with inflammation. This suggests lipids play an active role in managing the immune response and energy demands of acute illness, rather than just being passive storage molecules.

Ipragliflozin (an SGLT2 inhibitor) improves hepatic steatosis and liver dysfunction in patients with Type 2 Diabetes irrespective of body weight reduction.

If you have Type 2 Diabetes and fatty liver, taking Ipragliflozin (50mg daily) can improve your liver health markers (like ALT) even if you do not lose significant body weight. This suggests the drug helps move fat out of the liver into safer storage areas, offering a specific benefit for liver health independent of weight loss efforts.

Pharmacological agents that induce browning of white adipose tissue (WAT) or activate brown fat can improve glucose tolerance and insulin sensitivity independent of weight loss.

Improving your metabolic health doesn't always require weight loss. Activating your brown fat through methods like cold exposure can directly improve how your body handles glucose and insulin, offering benefits even if your weight stays the same.

Aging causes a progressive decline in mitochondrial reserve respiratory capacity (RRC), which sensitizes high-energy tissues (brain, heart, skeletal muscle) to bioenergetic exhaustion and increases the risk of age-related pathologies and cell death.

Your body's ability to handle sudden energy demands (like intense exercise or stress) declines with age because your mitochondria produce less 'spare' energy. This makes you more vulnerable to fatigue and tissue damage. However, in skeletal muscle, this decline is not permanent; regular endurance exercise can restore mitochondrial content and function, effectively rebuilding this safety margin.

Women exhibit higher skeletal muscle expression of GRB10 and ACVR2B compared to men, which may contribute to smaller muscle mass by inhibiting IGF-1 signaling and increasing myostatin activity.

This research highlights a biological basis for why women, on average, have less muscle mass than men, potentially due to higher levels of specific genes (GRB10 and ACVR2B) that inhibit muscle growth signals. For women, this means that building muscle may require specific attention to resistance training to overcome these inherent signaling constraints, rather than assuming equal ease of growth compared to men.

Carrying a high genetic burden of obesity-risk variants (FTO, SH2B1, MTCH2, MC4R, NEGR1, GNPDA2) causally increases total, abdominal, and gynoid adipose mass, which in turn drives a significantly higher risk of type 2 diabetes.

Your genes can make you heavier and increase your diabetes risk, but they don't dictate your fate. This study shows that genetic risk is largely mediated by body fat. While you can't change your DNA, you can manage the outcome by focusing on maintaining a healthy weight and metabolic health, as the genetic risk is not strong enough to justify ignoring lifestyle factors or relying on genetic tests for clinical decisions.